Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27420878 | 0.98 | KMT2A (0.38) | KMT2AFABP7FABP5MAPTPKM | |
| SCHEMBL27420738 | 0.95 | KMT2A (0.39) | KMT2AFABP7FABP5MAPTPKM | |
| SCHEMBL27420844 | 0.92 | KMT2A (0.41) | KMT2ATDP1CYP1A2CYP2C19 | |
| SCHEMBL27420760 | 0.89 | KMT2A (0.41) | KMT2ATDP1CYP1A2CYP2C19 | |
| SCHEMBL27420747 | 0.89 | KMT2A (0.42) | KMT2ATDP1CYP1A2CYP2C19 | |
| SCHEMBL27420775 | 0.87 | KMT2A (0.41) | KMT2ATDP1CYP1A2CYP2C19 | |
| SCHEMBL27420721 | 0.86 | KMT2A (0.35) | KMT2ATDP1 | |
| SCHEMBL27420855 | 0.86 | NAAA (0.42) | KMT2ATDP1CYP1A2CYP2C19 | |
| SCHEMBL27421425 | 0.78 | KMT2A (0.38) | KMT2AFABP7FABP5TDP1 | |
| SCHEMBL27420232 | 0.77 | FABP7 (0.43) | KMT2AFABP7FABP5TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092256-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-02 | — | — | WO | disclosed |